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The aims of the present study were to investigate how breast cancer (BC) subtypes and treatment affect time to
brain metastasis (TTBM). We retrospectively investigated 189 consecutive patients who were diagnosed with brain
metastasis (BM) from BC between 2000 and 2009 at Samsung Medical Center. We analyzed TTBM from initial
diagnosis of metastatic BC according to subtypes and trastzumab (T) administration before BM diagnosis. The
median age of 189 BM patients from BC was 48 years. We divided TTBM into four groups considering BC subtypes
and treatment; HR-positive/HER2-negative (n=45), HER2-positive with T before BM development (n=47), HER2-
positive without T before BM development (n=39), and TNBC (n=58). The median TTBMs for each group were
17.5 months, 13.7 months, 5.8 months, and 2.9 months, respectively (p<0.001). HER2-positive without T (HR 1.892,
p=0.008) and TNBC (HR 1.652, p=0.023) were independently associated with shorter TTBM. In multivariate analysis,
HER2-positive without T (hazard ratio 1.725, p=0.002) and TNBC (hazard ratio 1.579, p=0.022) were independent risk
factors for worse metastatic OS compared with HR-positive/HER2-negative subtype. TTBMs were shorter in patients
with HER2-positive without T and TNBC among BC subtypes. Prospective clinical study for high risk patients for
early BM is warranted.
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Breast cancer (BC) is the second-most common cancer
that spreads to the brain (Lin et al. 2004). The incidence
of brain metastasis (BM) from BC appears to be increas-
ing attributable to improved neuroimaging, increasing
numbers of BC patients, and prolonged survival due to
improved systemic therapies. Symptomatic BM in
patients with metastatic breast cancer (MBC) occurs in
10-16% of patients, revealing up to 30% when autopsy
diagnosis of BM is included (Santarelli et al. 2007;
Al-Shamy & Sawaya 2009). The median survival after de-
velopment of BM in BC patients is approximately 4–6 months
and 1– and 2-year survival rates are approximately 20% and
2%, respectively.
Traditionally, a number of risk factors for BM from
MBC have been reported to be associated with high tumor* Correspondence: imyh00@skku.edu
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in any medium, provided the original work is pgrade, a negative hormone receptor status, early-onset BC,
African-American ethnicity, HER2 overexpression or the
presence of lung and liver metastases. The median latency
between the initial diagnosis of BC and the onset of BM is
2 to 3 years, suggesting that BM usually occurs late in the
course of MBC. It has been shown by Heitz et al. (2009)
triple-negative or HER2-positive BC is associated with
higher and earlier BM development in the course of dis-
ease compared with ER+/HER2- subtype. However, the
how BC subtypes predispose to BM differently in their
longitudinal disease course and their relation with sys-
temic treatment have not been described well.
Recently it has been reported that the tool as nomo-
gram to predict subsequent BM in patient with MBC
with non-BM (Graesslin et al. 2010). And, we have
reported that new prognostic model to prediction of
outcomes for patients with BM reflecting the different
biologic features of BC, including treatment effect and
status of extracranial disease control (Ahn et al. 2012)
by refining the Sperduto’s BC-specific GPA index
(Sperduto et al. 2012) through analysis of a nomogramOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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tures of BCs. Thus, we need to incorporate time to BM
(TTBM) in addition to selection of enriching patients
and prediction prognosis of BM from BC.
We hypothesized that MBC patients may predispose
to BM differently during the disease courses according
to BC subtypes and treatments, and timing of BM may
affect metastatic survival.
In the present study, we aimed to describe how tumor
subtype and therapy-related factors of anti-HER2 treat-
ment differently affect TTBM in BC patients. Next, we
investigated whether TTBM influence on metastatic
overall survival in MBC patients.
Patients and methods
Patients’ cohort
From the data base in our institute, we identified 223
consecutive patients who were diagnosed with BM from
BC between 2000 and 2011 at Samsung Medical Center.
Among these, we excluded 25 patients who did not have
available IHC data of estrogen receptor (ER), progester-
one receptor (PgR), or HER2. An additional 9 patients
whose clinical data were incomplete were excluded, leav-
ing a final cohort of 189 patients (Figure 1). All patients
had histologically confirmed adenocarcinoma of the
breast in the primary and/or metastatic sites(s) by two
experienced pathologists who determined the primary
tumor characteristics. Clinical data including patients
characteristics, tumor subtype according to the status ofFigure 1 Patients’ cohort.immunohistochemical staining for ER, PgR, and HER2.
The status of ER and PgR positivity were defined by
Allred scoreof 3–8 by IHC using ER antibody
(Immunotech) and PgR antibody (Novocastra), respect-
ively.HER2 status was evaluated using an antibody
(DAKO)and/or fluorescence in situ hybridization (FISH).
Grades 0 and 1 for HER2 by IHC were defined as nega-
tive and grade 3 as positive. In patients with HER2 2+
by IHC, FISH was performed to confirm HER2 amplifi-
cation. Triple negativity was defined as a lack of ER,PgR,
and HER2 expressions.
Routine screening for BM was not performed. BM was
diagnosed using brain magnetic resonance imaging
(MRI) and/or surgical intervention when clinically
suspected. Treatment modalities for BM included symp-
tomatic management with corticosteroids, WBRT, surgi-
cal resection, SRS, and/or systemic treatment at
physician’s discretion.
Statistical analysis
Patient characteristics were compared using chi-square
and Fisher’s exact test (categorical variables). Time to
brain metastases (TTBM) was defined from the date of
initial diagnosis of distant metastasis to the date of BM
diagnosis. TTBM according to BC subtype and tras-
tuzumab treatment was assessed by Kaplan-Meier
methods and compared using log-rank test. Multivariate
analysis to assess prognostic factor for TTBM was
performed using a Cox-proportional hazards model, and
Table 1 Baseline characteristics of 189 breast cancer
patients with brain metastases
Characteristics Total N=189 (%)
Median age (range)
at initial diagnosis of distant metastasis 46 (25–85)
at initial diagnosis of BM 48 (26–87)





Invasive ductal carcinoma 163 (86%)
Invasive lobular carcinoma 3 (2%)
Others 10 (5%)
Unknown 13 (7%)







HER2-positive irrespective of HR status 86 (47%)
TNBC 58 (31%)
AntiHER2 Treatment among HER2-positive
patients (N=86)
Before BM diagnosis 47 (51%)
as an adjuvant treatment 12
as a neoadjuvant treatment 1
as a palliative treatment 34
After BM diagnosis 15 (17%)
No anti-HER2 treatment 24 (32%)
Overall Survival, median months
from initial distant metastases (mOS) 23.3
from initial BM diagnosis (BM-OS) 9.6
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initial diagnosis of primary BC, primary metastatic disease,
initial metastatic sites including liver, lung, or bone, BC
subtypes. BC subtypes were defined as follows: hormone
receptor (HR)-positive type was as ER and/or PgR posi-
tive with HER2-negative, HER2-positive type wasHER2-
positive irrespective of HR status, TN type was defined as
lack of ER, PgR, and HER2 expressions. In addition to
this, HER2-positive type was divided into two subtypes
according to the treatment of trastuzumab (T): HER2-
positive with T and HER2-positive without T. Metastatic
overall survival (mOS) was defined from the date of initial
diagnosis of distant metastases to the date of death. Meta-
static OS was assessed by Kaplan-Meier method and com-
pared using log-rank test according to BC subtypes.
Results
Patient characteristics
Patient demographics are displayed in Table 1. Median
age at diagnosis of BM was 48 years. Eighty-six percent
(n=163) of the patients had invasive ductal carcinoma
and the remaining had other pathologies. Ten percent
(n=18) of the patients was initially diagnosed as stage IV
metastatic disease. Among 189 patients, the proportion
of HR-positive/HER2-negaitve, HER2-positive irrespect-
ive of HR status, and TNBC was 23.8% (n=45), 46.5%
(n=86), and 30.7% (n=58), respectively. Among eighty
six HER2-positive patients, thirty seven patients were
HR-positive and forty nine patients were HR-negative.
Sixty two (72%) of eighty six HER2-positive patients had
received anti-HER2 treatment with trastuzumab in their
disease course, and the number of patients who received
trastuzumab before BM development was forty-seven
(55%). Trastuzumab was administered as neoadjuvant
treatment in one patient, as adjuvant treatment in twelve
patients, and as palliative treatment in remaining pa-
tients. Overall survival from initial diagnosis of distant
metastases (mOS), and from BM diagnosis (BM-OS) was
23.3 and 9.6 months, respectively.
Characteristics of BM development according to tumor
subtype
We subdivided patients into four groups according to ex-
pression of HR and HER2 and trastuzumab administration
before BM development. Characteristics according to sub-
type and trastuzumab treatment are featured in Table 2.
Median age at initial BM diagnosis was younger in TNBC
(median 45 years) and HER2-positive without trastuzumab
(median 46 years) than HR-positive/HER2-negative
patients (median 51 years) and HER2-positive with tras-
tuzumab (median 50 years) (p=0.005). Stage at MBC diag-
nosis, performance status at BM diagnosis, number of
brain metastases, site of initial distant metastasis, propor-
tion of concomitant leptomeningeal seeding at initial BMdiagnosis were not different among the four subgroups.
Brain was an initial metastatic site more frequently in
TNBC (38%) or HER2-positive without trastuzumab treat-
ment (37%) compared with in HR-positive/HER2-negative
(21%) or HER2-positive with trastuzumab administration
before BM (21%). Brain was the only metastatic site in
TNBC (21%, n=12) more frequently compared with other
subtypes (11%, n=15).
Time to brain metastases (TTBM)
Times to brain metastases from the primary BC diagno-
sis or from the metastatic BC were different according
to tumor subtype and trastuzumab effect. Median time







Without T* (N=39) With T* (N=47)
Age, median (range)
At initial distant mets 49 (30–85) 45 (25–68)) 46 (33–66) 44 (26–65) 0.145
At BM diagnosis 51 (30–87) 46 (26–70) 50 (34–67) 45 (26–67) 0.005
Stage at initial diagnosis 0.088
I/II 27 (61%) 14 (38%) 15 (30%) 25 (43%)
III 11 (23%) 19 (48%) 22 (48%) 24 (41%)
IV 4 (9%) 1 (2%) 7 (15%) 6 (10%)
unknown 3 (7%) 5 (12%) 3 (7%) 3 (5%)
Brain as initial metastatic site 9 (21%) 15 (37%) 10 (21%) 22 (38%) 0.112
Brain,the only metastatic site 5 (11%) 4 (10%) 6 (13%) 12 (21%) 0.142
Site of initial distant metastasis
Bone 18 (47%) 18 (50%) 15 (44%) 21 (38%) 0.705
Lung 14 (37%) 14 (39%) 11 (32%) 26 (47%) 0.535
Liver 5 (13%) 6 (17%) 13 (38%) 8 (15%) 0.036
Pleura 7 (18%) 5 (13%) 5 (16%) 8 (15%) 0.936
LMS‡ at BM diagnosis 7 (17%) 6 (15%) 6 (16%) 12 (21%) 0.824
ECOG PS at BM diagnosis 0.482
0-1 32 (72%) 27 (69%) 33 (70%) 35 (60%)
2 5 (12%) 6 (16%) 10 (22%) 13 (22%)
3-4 8 (19%) 5 (14%) 4 (9%) 10 (17%)
Number of brain metastasis 0.430
1 16 (36%) 10 (26%) 8 (17%) 17 (29%)
2-3 3 (7%) 8(21%) 8 (17%) 9 (16%)
≥3 24 (53%) 20 (51%) 31 (66%) 31 (53%)
missing 2 (4%) 1(3%) 0(0%) 1 (2%)
Extracranial systemic control at BM diagnosis 0.122
PR/SD 7 (16%) 6 (15%) 16 (34%) 9 (16%)
PD 27 (60%) 25 (64%) 20 (43%) 37 (64%)
No other systemic mets. 5 (11%) 4 (10%) 6 (13%) 12 (21%)
unknown 6 (13%) 4 (10%) 5 (11%) 0 (0%)
*T; trastuzumab, †TNBC; triple negative breast cancer, ‡LMS; leptomeningeal seeding.
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was 19.9 months in TNBC, 32.1 months in HER2-
positive without trastuzumab, 35.4 months in HER2-
positive with trastuzumab, and 59.8 months in HR-
positive/HER2-negative patients, respectively (p<0.001,
Figure 2A). Median time to brain metastases from diagnosis
of distant metastases was 2.9 months in TNBC, 5.8 months
in HER2-positive without trastuzumab, 13.7 months in
HER2-positive with trastuzumab, 17.5 months with
HR-positive/HER2-negative, respectively (p=0.001, Figure 2B).
In multivariate analysis, HER2-positive without tras-
tuzumab (hazard ratio 1.892, p=0.008) and TNBC (haz-
ard ratio 1.652, p=0.023) were independent prognosticfactors for shorter TTBM compared with HR-positive/
HER2-negative subtype. Patients presenting with bone
metastases as first distant metastatic sites was associated
with longer TTBM (hazard ratio 0.695, p=0.033), signifi-
cantly. Age and primary metastatic disease, were not as-
sociated with TTBM in multivariate analysis (Table 3).
Metastatic overall survival according to BC subtypes and
trastuzuamb effect
Metastatic overall survivals from the date of diagnosis of dis-
tant metastasis to death were significantly different according
to the four BC subtypes incorporated with trastuzumab ef-
fect (Figure 3). Median time to death from distant metastases
Figure 2 Time to brain metastases (TTBM) according to breast cancer subtype. (A)Time to brain metastases from diagnosis of primary
breast cancer according to subtype and trastuzumab administration before brain metastases development. (B)Time to brain metastases from
initial diagnosis of metastatic breast cancer according to subtype and trastuzumab administration before brain metastases development.
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positive without trastuzumab, 26.9 months in HER2-positive
with trastuzumab, and 33.2 months in HR-positive/HER2-
negative patients, respectively (p=0.020, Figure 3). In
multivariate analysis, HER2-positive without trastuzumab
(hazard ratio 1.725, p=0.002) and TNBC (hazard ratio
1.579, p=0.022) were independent risk factors for worse
metastatic OS compared with HR-positive/HER2-negative
subtype.
Discussion
Recent improvements of systemic treatments including
new cytotoxic agents and third generation aromatase in-
hibitors (AI) have brought to longer survival in patientsTable 3 Cox-regression multivariate analysis of predictive
factors for time to brain metastases (TTBM) from initial
distant metastases
Characteristics HR (95% C.I.) P-value
Age at first diagnosis
of primary disease
1.001 (0.985-1.018) 0.863
Stage IV at initial diagnosis
of primary BC
0.843 (0.475-1.495) 0.559
Site of initial distant metastases
Bone 0.695 (0.498-0.969) 0.033
Lung 1.138 (0.811-1.597) 0.453
Liver 1.431 (0.934-2.190) 0.099
Subtype with trastuzumab effect
HR-positive/HER2-negative reference
HER2-positive withoutTrastuzumab 1.892 (1.177-3.040) 0.008
HER2-positive with Trastuzumab 1.064 (0.650-1.741) 0.656
TNBC 1.652 (1.071-2.546) 0.023with MBC. Prominently, incorporation of targeted therap-
ies, such as trastuzumab, in HER2-positive BC has
changed the natural history of this disease, prolonging sur-
vival. Consequently, many women now survive long
enough to develop CNS disease. It also has emphasized
local treatment modalities, such as whole brain radiation,
stereotactic surgery, and tumor removal (Chargari et al.
2010; Suh 2010; Kased et al. 2009; Muacevic et al. 2004).
With BM occurring as the result of poor systemic dis-
ease control, predicting the timing of BM development
may provide rationale for early intervention and treatingFigure 3 Overall survival from the initial diagnosis of distant
metastases according to breast cancer subtype.
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retrospective single-center study analyzing TTBM accor-
ding to BC subtype and anti-HER2 treatment trastuzumab
was based on a relatively large cohort of patients with BM
from BC. The distributions of HER2-positive and TNBC
among BM patients from BC were higher than in those of
the general proportion of BC patients, which reflects pre-
dilection to BM of HER2-positive and TNBC BCs
(Slimane et al. 2004; Sanna et al. 2007; Ryberg et al. 2005;
Lin et al. 2008; Heitz et al. 2009; Pestalozzi et al. 2006). In
terms of TTBM from initial diagnosis of metastatic disease,
median TTBM was significantly shorter in TNBC patients
(2.9 months) and HER2-positive without trastruzumab
treatment (5.8 months) compared patients with HR-
positive/HER2-negative (17.5 months) or HER2-positive
patients who received trastuzumab (13.7 months). This
propensity of HER2-positive and TNBC to early BM occur-
rence is consistent with previous studies by Heitz et al.
(2009).This result is also supported by other translational re-
sults (Sarrio et al. 2008; Lin et al. 2004; Duchnowska et al.
2009). However, they did not investigate anti-HER2 treatment
effect on TTBM. In the present study, TTBM from initial pri-
mary BC was not different according to trastuzumab treat-
ment but TTBM from initial diagnosis of distant metastases
was significantly longer in HER2-positive patients with
trastuzumab treatment. In multivariate analysis, both HER2-
positive without trastuzumab treatment and TNBC were in-
dependently associated with earlier BM occurrence.
Prognostic model for BM from BC patients were
reported and there is biologic evidence for higher pro-
pensity for BM in HER2-positive and TNBC patients
(Ahn et al. 2012; Heitz et al. 2009; Sperduto et al. 2012), al-
though routine screening of BM for high risk patients did
not show definite survival benefit (Niwinska et al. 2007).
While general therapeutic nihilism should be avoided, it is
still important to recognize that the number of BM, the ex-
tent of the systemic disease, and also the BC subtype have
to be taken into account when choosing individual treat-
ment regimens. Finally, special emphasis will be put on
established and future approaches to prevent BM. Incorp-
oration of TTBM to prediction of prognosis in BM from
BC patients may facilitate screening at most risky period,
potential development of possible prophylactic strategies,
and choice of treatment modalities, which are ready for
prospective clinical trial.
This study is limited in that the study population is
not the entire patients with BC diagnosis, but the pa-
tients who diagnosed with BM from BC, and therefore
we could not evaluate the actual incidence of BM
exactly. Instead, we have evaluated the TTBM from the
time of first diagnosis of metastatic BC according to sub-
type and targeted treatment among BM patients.
Considering high cost of screening brain MRI, the pro-
spective clinical trial selecting the patients’ population athigh risk of BM who has significant benefit from screen-
ing and treating asymptomatic BM is crucial. Given that
over 50% of BM in HER2-positive and TNBC occur in
the first year after diagnosis of metastatic BC in this
study which is compatible with previous reports (Heitz
et al. 2009), it might be reasonable to confine candidates
to screen asymptomatic BM to HER2-positive and
TNBC population, for more risky period after initial
diagnosis of metastatic disease, and screening should be
considered incorporated with systemic disease control.
Moreover, in these cases of BM development with well
controlled extracranial systemic disease, the optimal
treatment strategy is questionable whether systemic
chemotherapy regimen should be changed or maintained
and how local therapy should be combined with sys-
temic treatments, especially for patients with BM as the
only progression site.
Conclusions
The present study identified HER2-positiveBC without
trastuzumab treatment and TNBC as independent risk
factors for shorter TTBM from the initial distant metas-
tasis. Incorporating prognostic index, TTBM may pro-
vide the rational approach to plan prospective clinical
trial whether there is a population in which screening at
most risky period or potential prophylactic strategies for
BM could have clinical benefit.
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